The role of metals in modulating metalloprotease activity in the AD brain.
Biometals such as copper and zinc have an important role in Alzheimer's disease (AD). Accumulating evidence indicates that copper homeostasis is altered in AD brain with elevated extracellular and low intracellular copper levels. Studies in animals and cell cultures have suggested that increasing intracellular copper can ameliorate AD-like pathology including amyloid deposition and tau phosphorylation. Modulating copper homeostasis can also improve cognitive function in animal models of AD. Treatments are now being developed that may result in redistribution of copper within the brain. Metal ligands such as clioquinol (CQ), DP-109 or pyrrolidine dithiocarbamate (PDTC) have shown promising results in animal models of AD, however, the actual mode of action in vivo has not been fully determined. We previously reported that CQ-metal complexes were able to increase intracellular copper levels in vitro. This resulted in stimulation of phosphoinositol-3-kinase activity and mitogen activated protein kinases (MAPK). Increased kinase activity resulted in up-regulated matrix metalloprotease (MMP2 and MMP3) activity resulting in enhanced degradation of secreted A beta. These findings are consistent with previous studies reporting metal-mediated activation of MAPKs and MMPs. How this activation occurs is unknown but evidence suggests that copper may be able to activate membrane receptors such as the epidermal growth factor receptor (EGFR) and result in downstream activation of MAPK pathways. This has been supported by studies showing metal-mediated activation of EGFR through ligand-independent processes in a number of cell-types. Our initial studies reveal that copper complexes can in fact activate EGFR. However, further studies are necessary to determine if metal complexes such as CQ-copper induce up-regulation of A beta-degrading MMP activity through this mechanism. Elucidation of this pathway may have important implications for the development of metal ligand based therapeutics for treatment of AD and other neurodegenerative disorders.
Filiz
Gulay
G
Department of Pathology and the Centre for Neuroscience, The University of Melbourne, Melbourne, VIC 3010, Australia.
Price
Katherine A
KA
Caragounis
Aphrodite
A
Du
Tai
T
Crouch
Peter J
PJ
White
Anthony R
AR
D000544:Alzheimer Disease / Q000503:physiopathology*; D000682:Amyloid / Q000187:drug effects / Q000378:metabolism; D016229:Amyloid beta-Peptides / Q000378:metabolism; D000818:Animals; D001921:Brain / Q000187:drug effects* / Q000201:enzymology / Q000503:physiopathology*; D018929:Cell Culture Techniques; D002614:Chelating Agents / Q000494:pharmacology* / Q000627:therapeutic use; D007464:Clioquinol / Q000627:therapeutic use; D003300:Copper / Q000737:chemistry / Q000378:metabolism / Q000494:pharmacology; D004195:Disease Models, Animal; D004533:Egtazic Acid / Q000031:analogs & derivatives / Q000627:therapeutic use; D004789:Enzyme Activation / Q000187:drug effects; D066246:ErbB Receptors / Q000187:drug effects / Q000378:metabolism; D006801:Humans; D042541:Intracellular Space / Q000378:metabolism; D053505:Matrix Metalloproteinases, Secreted / Q000378:metabolism*; D020928:Mitogen-Activated Protein Kinases / Q000187:drug effects / Q000378:metabolism; D058225:Plaque, Amyloid / Q000187:drug effects; D011392:Proline / Q000031:analogs & derivatives / Q000627:therapeutic use; D013859:Thiocarbamates / Q000627:therapeutic use; D014131:Trace Elements / Q000378:metabolism; D015032:Zinc / Q000378:metabolism
D000682:Amyloid; D016229:Amyloid beta-Peptides; D002614:Chelating Agents; C428063:DP-109; D013859:Thiocarbamates; D014131:Trace Elements; C066229:prolinedithiocarbamate; D004533:Egtazic Acid; D003300:Copper; D007464:Clioquinol; D011392:Proline; D066246:ErbB Receptors; D020928:Mitogen-Activated Protein Kinases; D053505:Matrix Metalloproteinases, Secreted; D015032:Zinc